Stock Scorecard
Stock Summary for Harmony Biosciences Holdings Inc (HRMY) - $35.77 as of 7/28/2026 9:23:17 PM EST
Total Score
13 out of 30
Safety Score
35 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for HRMY
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for HRMY
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for HRMY
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for HRMY
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for HRMY (35 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 4 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for HRMY
Financial Details for HRMY
Company Overview |
|
|---|---|
| Ticker | HRMY |
| Company Name | Harmony Biosciences Holdings Inc |
| Country | N/A |
| Description | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/4/2026 |
Stock Price History |
|
| Last Day Price | 35.77 |
| Price 4 Years Ago | 55.10 |
| Last Day Price Updated | 7/28/2026 9:23:17 PM EST |
| Last Day Volume | 886,062 |
| Average Daily Volume | 857,783 |
| 52-Week High | 40.87 |
| 52-Week Low | 25.52 |
| Last Price to 52 Week Low | 40.16% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 29.30 |
| Sector PE | 72.02 |
| 5-Year Average PE | 19.34 |
| Free Cash Flow Ratio | 3.51 |
| Industry Free Cash Flow Ratio | 35.42 |
| Sector Free Cash Flow Ratio | 35.62 |
| Current Ratio Most Recent Quarter | 3.58 |
| Total Cash Per Share | 10.18 |
| Book Value Per Share Most Recent Quarter | 15.73 |
| Price to Book Ratio | 2.15 |
| Industry Price to Book Ratio | 12.27 |
| Sector Price to Book Ratio | 9.40 |
| Price to Sales Ratio Twelve Trailing Months | 2.17 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.24 |
| Sector Price to Sales Ratio Twelve Trailing Months | 30.46 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 57,893,000 |
| Market Capitalization | 2,070,832,610 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -29.50% |
| Annual Earnings Growth | 9.07% |
| Reported EPS 12 Trailing Months | 2.48 |
| Reported EPS Past Year | 0.79 |
| Reported EPS Prior Year | 3.35 |
| Net Income Twelve Trailing Months | 145,615,000 |
| Net Income Past Year | 158,687,000 |
| Net Income Prior Year | 145,493,000 |
| Quarterly Revenue Growth YOY | 16.60% |
| 5-Year Revenue Growth | 40.30% |
| Operating Margin Twelve Trailing Months | 17.30% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 589,398,000 |
| Total Cash Past Year | 752,502,000 |
| Total Cash Prior Year | 453,001,000 |
| Net Cash Position Most Recent Quarter | 450,584,000 |
| Net Cash Position Past Year | 608,839,000 |
| Long Term Debt Past Year | 143,663,000 |
| Long Term Debt Prior Year | 163,016,000 |
| Total Debt Most Recent Quarter | 138,814,000 |
| Equity to Debt Ratio Past Year | 0.86 |
| Equity to Debt Ratio Most Recent Quarter | 0.87 |
| Total Stockholder Equity Past Year | 870,218,000 |
| Total Stockholder Equity Prior Year | 659,155,000 |
| Total Stockholder Equity Most Recent Quarter | 910,349,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 341,790,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 5.90 |
| Free Cash Flow Past Year | 347,889,000 |
| Free Cash Flow Prior Year | 218,668,000 |
Options |
|
| Put/Call Ratio | 3.78 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.18 |
| MACD Signal | 0.53 |
| 20-Day Bollinger Lower Band | 25.41 |
| 20-Day Bollinger Middle Band | 31.65 |
| 20-Day Bollinger Upper Band | 37.90 |
| Beta | 0.94 |
| RSI | 48.88 |
| 50-Day SMA | 32.95 |
| 150-Day SMA | 32.79 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 7/28/2026 1:03:25 AM EST |